China Didn't Ask Permission to Become a Biotech Superpower

For decades, the American Society of Clinical Oncology's annual meeting in Chicago was basically a showcase for American and European medicine. Not anymore.

This year, one of the conference's five headline presentation slots goes to a clinical trial conducted entirely in China. According to The Business Times, that appears to be a first in the meeting's history. Dr. Otis Brawley, a Johns Hopkins professor who has attended every ASCO meeting since 1989, put it plainly: "This tells us that the Chinese biotech industry has arrived."

It has.

The Numbers Don't Lie

A study published last month in the Journal of the American Medical Association — co-authored by Georgetown University researchers So-Yeon Kang and Yunan Ji — tracked early-stage drug programs, the pipeline that determines what drugs get approved and funded in the future.

In 2015, China had roughly 800 such programs. By 2024, that number exceeded 6,000. That's a 650% increase in under a decade.

The U.S. grew too — from around 5,000 programs to 7,000. But America's global share of early-stage drug programs dropped from 50% to 33% over that same period.

Then came 2025. According to data crunched by Kang and Ji, as reported by Livemint, China overtook the U.S. in early-stage drug development in the second quarter of 2025. That already happened.

This Is a Trade Story Too

The Atlantic Council dug into the trade numbers, and they tell a different story than the panicked "China controls our medicine supply" narrative you hear from both parties.

U.S. pharmaceutical imports from China grew 485% between 2020 and 2022 — from $2.1 billion to $10.3 billion. China is now the fourth-largest supplier of medicines to the United States, behind Ireland, Germany, and Switzerland.

The trade is broadly balanced, however. The U.S. imported $10.2 billion in pharma from China while exporting $9.3 billion back. This isn't a one-way dependency. It's mutual. And it's not cheap knockoffs driving the growth — it's advanced medicines like cancer treatments and antibiotics.

The Atlantic Council's assessment: China does NOT currently have a stranglehold on U.S. medicine supply chains. But they recommend regular supply-chain mapping so policymakers can act before it becomes a real vulnerability. That's a reasonable, non-hysterical take that rarely makes headlines.

What Washington Is Actually Doing About It

Not enough. And both parties own that.

President Trump signed legislation barring government agencies from contracting with certain foreign biotech service providers in adversarial countries — a targeted measure, according to The Business Times. Fine. That's a start.

But Livemint points out the contradiction: Trump is simultaneously pushing another year of cuts to America's major science agencies — the same agencies that fund the foundational research that seeds commercial biotech breakthroughs. You can't gut the seed corn and then complain the harvest is shrinking.

China outspent the U.S. on R&D as early as two years ago, according to the OECD. America's response has been budget fights, NIH funding debates, and a brain drain of top researchers.

Dr. Robert Califf, former FDA commissioner, told The Business Times: "The U.S. is being seriously threatened." He's not wrong.

What Mainstream Coverage Is Getting Wrong

The NYT framed this as a story about "alarm" and "waning dominance" — classic anxiety journalism. The left-leaning framing focuses on Trump's science cuts as THE cause.

The right-leaning media mostly ignores this story entirely, which is its own failure. When Fox covers China biotech at all, it's usually in the context of spying or IP theft — real concerns, but they crowd out the bigger strategic picture.

Neither side is asking the fundamental question: Why did we let a decade of Chinese investment go largely unnoticed while we argued about culture wars and government shutdowns?

China put biotech at the center of its national economic strategy. The U.S. treated it like a free-market afterthought.

What This Means for Regular Americans

Short term: potentially good news. More drug development globally means more competition, more treatments, and possibly lower prices. Global drugmakers have already inked hundreds of billions of dollars in licensing deals with Chinese biotech companies, according to Livemint. Those drugs will reach American patients.

Long term: if China controls the patents, the data, and the clinical infrastructure behind the next generation of cancer drugs, America loses leverage — in trade negotiations, in national security, and in a crisis scenario where that supply gets cut off.

The U.S. still leads. But the gap is closing fast, and the trajectory is NOT in our favor.

We built the best biotech ecosystem in the world over 50 years. We can fumble it in a decade if we keep treating science funding like a political football.

China isn't waiting for us to figure that out.